论文部分内容阅读
目的观察丹参酮ⅡA磺酸钠注射液治疗老年肺心病的疗效。方法将58例老年肺心病急性加重期患者随机分为治疗组30例和对照组28例,两组均采用抗感染、平喘化痰、适当强心利尿及低流量吸氧等常规治疗。治疗组在常规综合治疗的基础上加用丹参酮ⅡA磺酸钠注射液80mg加5%葡萄糖注射液250m l,静脉滴注,每日1次,共治疗14d。对照组给予常规治疗,其余疗程与治疗组相同。结果治疗组患者治疗后全血黏度、血浆比黏度、红细胞聚集指数、血细胞比容、血小板聚集率均显著下降(P<0.01或P<0.05),与对照组比较,以上指标亦有显著下降(P<0.05)。治疗组临床总有效率及显效率分别为93.4%及53.3%,对照组分别为71.4%及25.0%。治疗组疗效明显优于对照组(P<0.05)。治疗期间未见丹参酮ⅡA磺酸钠注射液引起的严重不良反应。结论丹参酮ⅡA磺酸钠注射液能显著改善慢性肺心病急性加重期患者的血流动力学,故为治疗肺心病的一种安全有效的药物。
Objective To observe the efficacy of sodium tanshinone Ⅱ A sulfonate injection in the treatment of pulmonary heart disease in the elderly. Methods Fifty-eight elderly patients with acute exacerbation of pulmonary heart disease were randomly divided into treatment group (n = 30) and control group (n = 28). Both groups were given conventional therapy such as anti-infective, antiasthmatic phlegm, proper cardiac diuretic and low-flow oxygen inhalation. Treatment group in the conventional comprehensive treatment based on the use of tanshinone Ⅱ A sodium sulfonate injection 80mg plus 5% glucose injection 250ml, intravenous infusion, once daily for a total of 14 days. The control group given conventional treatment, the rest of the treatment and treatment group the same. Results After treatment, the whole blood viscosity, plasma specific viscosity, erythrocyte aggregation index, hematocrit and platelet aggregation rate in treatment group decreased significantly (P <0.01 or P <0.05), and the above indexes also decreased significantly P <0.05). The total clinical effective rate and markedly effective rate in the treatment group were 93.4% and 53.3% respectively, while that in the control group was 71.4% and 25.0% respectively. The treatment group was significantly better than the control group (P <0.05). No serious side effects caused by tanshinone Ⅱ A sodium sulfonate injection were observed during the treatment. Conclusion Sodium tanshinone Ⅱ A sulfonate injection can significantly improve hemodynamics in patients with acute exacerbation of chronic pulmonary heart disease, and is therefore a safe and effective drug for the treatment of pulmonary heart disease.